Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.56 |
| ▸ | CD44 | P16070 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | PRCP | P42785 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4780279 | 0.78 | PNMT (0.58) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL27831591 | 0.75 | PNMT (0.91) | PNMTCD44MAOBHTR2CPRCP | |
| SCHEMBL2911557 | 0.75 | — | — | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.75 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.75 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.75 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| SCHEMBL4042067 | 0.75 | — | — | |
| SCHEMBL64698 | 0.75 | — | — | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL16099356 | 0.73 | PNMT (0.86) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL16291557 | 0.73 | PNMT (0.86) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | PNMT 2275/4885CD44 2182/4885MAOB 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.